Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

The monoclonal antibodies cetuximab and panitumumab, directed against the epidermal growth factor receptor (EGFR), are licensed for the treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Such ‘molecular restriction’ derived from post-hoc analyses of randomized trials and from other ret...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Loupakis, Fotios, Cremolini, Chiara, Fontanini, Gabriella, Stasi, Irene, Salvatore, Lisa, Falcone, Alfredo
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2009
Soggetti:
Reviews
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126002/
https://ncbi.nlm.nih.gov/pubmed/21789120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834009348984
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi